Mesa Laboratories - MLAB Stock Forecast, Price & News

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Mesa Laboratories Stock Up 2.9 %

MLAB Stock opened at $196.14 on Friday. The business has a 50 day moving average of $200.31 and a 200 day moving average of $228.93. The firm has a market cap of $1.04 billion, a PE ratio of -653.78 and a beta of 0.52. Mesa Laboratories has a twelve month low of $178.32 and a twelve month high of $333.42. The company has a quick ratio of 2.29, a current ratio of 2.90 and a debt-to-equity ratio of 0.57.

Mesa Laboratories (NASDAQ:MLAB - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $0.52 EPS for the quarter, missing the consensus estimate of $1.57 by ($1.05). The firm had revenue of $50.45 million for the quarter, compared to analysts' expectations of $52.63 million. Mesa Laboratories had a negative net margin of 0.78% and a positive return on equity of 5.80%. On average, research analysts forecast that Mesa Laboratories will post 7.6 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 15th. Shareholders of record on Wednesday, August 31st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date is Tuesday, August 30th. Mesa Laboratories's payout ratio is -213.33%.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Mesa Laboratories from a "hold" rating to a "sell" rating in a report on Friday, August 5th.

Insider Transactions at Mesa Laboratories

In related news, CEO Gary M. Owens sold 1,756 shares of the stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $188.22, for a total transaction of $330,514.32. Following the sale, the chief executive officer now directly owns 21,640 shares of the company's stock, valued at $4,073,080.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Mesa Laboratories news, SVP Brian David Archbold sold 392 shares of the firm's stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $188.22, for a total value of $73,782.24. Following the transaction, the senior vice president now directly owns 813 shares of the company's stock, valued at $153,022.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Gary M. Owens sold 1,756 shares of the company's stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $188.22, for a total transaction of $330,514.32. Following the sale, the chief executive officer now directly owns 21,640 shares of the company's stock, valued at approximately $4,073,080.80. The disclosure for this sale can be found here. Insiders sold 8,062 shares of company stock worth $1,618,881 over the last quarter. 5.50% of the stock is currently owned by insiders.